v3.25.4
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales $ 16,382 $ 15,193 $ 16,126
Selling, general and administrative 10,733 10,816 10,504
Research and development 15,789 17,938 30,531
Other current assest 43,516 38,782  
Accrued and other current liabilities 14,468 15,694  
Amortization expense for intangible assets 2,800 2,400 2,000
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement $ 1,886 $ 1,481 $ 1,296
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Sales Sales Sales
Cost of sales $ 338 $ 378 $ 311
Selling, general and administrative 133 165 192
Research and development 36 77 79
Other current assest 451 424  
Other assets 125 0  
Accrued and other current liabilities 6 713  
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 1,450 1,311 1,199
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 436 170 $ 97
Upfront payments recognized as revenue 150    
Milestone payments $ 175    
AstraZeneca | Koselugo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization expense for intangible assets   $ 48